Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $10.00

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received an average rating of “Hold” from the nine brokerages that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $10.00.

Several research analysts have issued reports on ZNTL shares. Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday. Guggenheim lowered their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. SG Americas Securities LLC boosted its stake in shares of Zentalis Pharmaceuticals by 115.6% in the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after buying an additional 30,240 shares in the last quarter. Barclays PLC lifted its stake in shares of Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after purchasing an additional 11,748 shares during the period. XTX Topco Ltd boosted its holdings in Zentalis Pharmaceuticals by 8.7% during the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock worth $714,000 after buying an additional 15,597 shares in the last quarter. Quarry LP acquired a new position in Zentalis Pharmaceuticals during the third quarter worth about $55,000. Finally, Paloma Partners Management Co purchased a new position in Zentalis Pharmaceuticals in the third quarter valued at about $37,000.

Zentalis Pharmaceuticals Stock Down 3.5 %

NASDAQ:ZNTL opened at $2.22 on Friday. The stock’s 50 day moving average price is $3.05 and its 200 day moving average price is $3.34. The company has a market capitalization of $158.20 million, a PE ratio of -0.89 and a beta of 1.86. Zentalis Pharmaceuticals has a 52-week low of $2.13 and a 52-week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.